Precision Biosciences (DTIL) EPS (Weighted Average and Diluted) (2020 - 2026)
Precision Biosciences (DTIL) reported EPS (Weighted Average and Diluted) of -$0.75 for Q1 2026, up 66.06% year-over-year from -$0.45 in Q1 2025, and down 129.07% quarter-over-quarter from $2.58 in Q4 2025.
Precision Biosciences (DTIL) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.75 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.75, up 66.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.14 (up 15.42% YoY), and the FY2025 annual result was -$3.56, down 442.31% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$0.75 in Q1 2026 per DTIL's latest filing, from $2.58 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $4.67 in Q2 2024 and troughed at -$37.06 in Q4 2022.
- A 5-year average of -$3.19 and a median of -$1.84 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2024: EPS (Weighted Average and Diluted) plunged 9652.63% in 2022, then jumped 683.75% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$37.06 in 2022, then jumped by 90.88% to -$3.38 in 2023, then climbed by 18.93% to -$2.74 in 2024, then jumped by 194.16% to $2.58 in 2025, then tumbled by 129.07% to -$0.75 in 2026.
- Business Quant data shows DTIL's EPS (Weighted Average and Diluted) at -$0.75 in Q1 2026, $2.58 in Q4 2025, and -$1.84 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Precision Biosciences | 168.99 Mn | 67.81 Mn | - | -0.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.75 |
| Dec 31, 2025 | 2.58 |
| Sep 30, 2025 | -1.84 |
| Jun 30, 2025 | -2.13 |
| Mar 31, 2025 | -2.21 |
| Dec 31, 2024 | -2.74 |
| Sep 30, 2024 | -2.25 |
| Jun 30, 2024 | 4.67 |
| Mar 31, 2024 | 1.70 |
| Dec 31, 2023 | -3.38 |
| Sep 30, 2023 | -2.10 |
| Jun 30, 2023 | -0.80 |
| Mar 31, 2023 | -6.75 |
| Dec 31, 2022 | -37.06 |
| Sep 30, 2022 | -0.22 |
| Jun 30, 2022 | -0.46 |
| Mar 31, 2022 | -0.46 |
| Dec 31, 2021 | -0.38 |
| Sep 30, 2021 | -0.19 |
| Jun 30, 2021 | 0.36 |